Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos(t)ide analogue treatment determined by MALDI-TOF MS

Clin Microbiol Infect. 2015 Mar;21(3):288.e1-4. doi: 10.1016/j.cmi.2014.10.004. Epub 2014 Oct 29.

Abstract

Minor drug-resistant variants may preexist in every subject infected with hepatitis B virus (HBV). However, understanding the dynamic of genotypic evolution within the HBV population requires accurately following allele frequencies through time. We used MALDI-TOF MS (matrix-assisted laser desorption-ionization time-of-flight mass spectrometry) for localization and quantitative allele frequency detection to investigate preexisting HBV quasispecies and the genotypic evolution of drug-resistant variants during nucleos(t)ide analogue therapy. We found a significant difference between the genotypic evolution of drug-resistant variants depending on response to treatment.

Keywords: Analogue; Drug resistance; HBV; MALDI-TOF MS; Quasispecies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use
  • DNA, Viral
  • Drug Resistance, Viral*
  • Female
  • Genetic Variation*
  • Genome, Viral*
  • Genotype
  • Hepatitis B / diagnosis
  • Hepatitis B / drug therapy
  • Hepatitis B / virology*
  • Hepatitis B virus / classification
  • Hepatitis B virus / drug effects*
  • Hepatitis B virus / genetics*
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Serogroup
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
  • Treatment Outcome
  • Viral Load

Substances

  • Antiviral Agents
  • DNA, Viral